Lipid Indices vs Anthropometric Indices in Metabolic Syndrome and Type 2 Diabetes Mellitus

Asha Augusthy; Suchanda Sahu; Ashok Kumar Jeppu

doi:10.21276/apalm.3060

Asha Augusthy Dept of Biochemistry, Sree Narayana Institute of Medical Sciences, Ernakulam, Kerala, India
Suchanda Sahu Department of Biochemistry, All India Institute of Medical Sciences, Sijua, Bhubaneshwar, Odisha, India
Ashok Kumar Jeppu Biochemistry unit, International Medical School, Management and Science University, Shah Alam, Selangor, Malaysia

DOI: https://doi.org/10.21276/apalm.3060

Keywords: Metabolic syndrome, Diabetes mellitus, Body mass index, body shape index, visceral adiposity index, lipid accumulation factor

Abstract

Background: Diabetes mellitus is a metabolic disease known by chronic hyperglycemia which results from defective insulin action and secretion. Metabolic Syndrome consists of a constellation of metabolic abnormalities that confer increased risk of diabetes mellitus. The aim of our study is to find out whether non-invasive, clinically measurable surrogates could be useful in identifying body fat distribution and help predict metabolic syndrome and diabetes risk and to compare the performance of anthropometric indices with lipid indices in identifying metabolic syndrome and diabetes. Methods: 50 individuals with metabolic syndrome ,50 individuals with type 2 diabetes mellitus and 50 controls were selected by purposive sampling technique. For cases and controls history was taken, physical examination was done .Fasting blood sugar, Serum High density lipoprotein and Serum Triglyceride levels were estimated. Body mass index, a body shape index, visceral adiposity index, lipid accumulation factor was calculated. Results: The mean values visceral adiposity index, lipid accumulation factor were significantly increased (p<0.001) in cases compared to controls. Conclusion: Our study concluded that lipid indices visceral adiposity index, lipid accumulation factor is better than anthropometric indices like body mass index, a body shape index in predicting metabolic syndrome and type 2 diabetes mellitus. Anthropometric indices when used should be correlated with metabolic variables and clinical symptoms.

References

Augusthy A, Jeppu AK, Sahu S, Jawalekar S, Marakala V, Iqbal S. A study of liver functions in metabolic syndrome and Type 2 diabetes mellitus. Int J Med Res Rev 2016;4(4):470-475.

Yashavanth HS, Bharath MS. Comparison of body mass index and lipid accumulation product as a better indicator of metabolic syndrome. Int J Adv Med 2017;4:728-33.

Amato et al.: Cut-off points of the visceral adiposity index (VAI) identifying a visceral adipose dysfunction associated with cardiometabolic risk in a Caucasian Sicilian population. Lipids in Health and Disease. 2011;10:183.

Amato MC, Pizzolanti G, Torregrossa V, Misiano G, Milano S, et al. Visceral adiposity index (VAI) is predictive of an altered adipokine profile in patients with Type 2 Diabetes.2014;PLoS ONE 9: e91969.

Matthews D, Hosker J, Rudenski A, Naylor BA, Treacher DF, et al.Homeostasis model assessment: insulin resistance and β-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia ,1985;28: 412-419.

Stefan N, Haring HU, Hu FB, Schulze MB.Metabolically healthy obesity: epidemiology, mechanisms, and clinical implications. Lancet Diabetes Endocrinol,2013; 1: 152-162.

Gomez‑Peralta et al. Diabetol Metab Syndr 2018;10:21.

C Xia, R Li, S Zhang, L Gong, W Ren, Z Wang , Q Li. Lipid accumulation product is a powerful index for recognizing insulin resistance in non-diabetic individuals. European Journal of Clinical Nutrition 2012; 66: 1035–1038.

Huang PL. A comprehensive definition for metabolic syndrome. Dis Model Mech. 2009 May-Jun;2(5-6):231-7.

Amato MC, Giodano C, Galia M, Criscimanna A, Vitabile S, et al.Visceral Adiposity Index. Diabetes Care;2010 33: 920-922.

Krakauer NY, Krakauer JC. A new body shape index predicts mortality hazard independently of body mass index. PLoS ONE. 2012;7(7):e39504.

G. Bedogni, H. S. Kahn, S. Bellentani, and C. Tiribelli. A simple index of lipid overaccumulation is a good marker of liver steatosis. BMC Gastroenterology 2010;10(98).

Kirk, E. P., & Klein, S. Pathogenesis and pathophysiology of the cardiometabolic syndrome. The Journal of Clinical Hypertension, 2009;11(12), 761–765.

Yan, L. L. et al. Midlife body mass index and hospitalization and mortality in older age.Jama.2006; 295, 190–198.

Zhang Y, Fu J, Yang S, Yang M, Liu A, et al. Prevalence of metabolically obese but normal weight (MONW) and metabolically healthy but obese (MHO) in Chinese Beijing urban subjects. Biosci Trends.2017; 11: 418-426.

Wu J, Gong L, Li Q, Hu J, Zhang S, Wang Y, Zhou H, Yang S & Wang Z. A Novel Visceral Adiposity Index for Prediction of Type 2 Diabetes and Pre-diabetes in Chinese adults: A 5-year prospective study. Scientific Reports 7: 13784 .

Wang, Y. et al. Predictive value of visceral adiposity index for type 2 diabetes mellitus: A 15-year prospective cohort study. Herz40,2015;(3), 277–281.

Unger RH, Scherer PE: Gluttony, sloth and the metabolic syndrome: a roadmap to lipotoxicity. Trends Endocrinol Metab 2010, 21:345-352.

Fujita M., Sato Y., Nagashima K., Takahashi S., Hata A. Predictive power of a body shape index for development of diabetes, hypertension, and dyslipidemia in Japanese adults: A retrospective cohort study. PLoS ONE. 2015;10:e0128972.

Khan SH, Shahid R, Fazal N, Ijaz A. Comparison of various abdominal obesity measures for predicting metabolicsyndrome, diabetes, nephropathy, dyslipidemia. J Coll Physicians Surg Pak 2019; 29(12):1159-1164.

Bawadi H, Abouwatf M, Alsaeed S, Kerkadi A,Shi Z Body Shape Index Is a Stronger Predictor of Diabetes. Nutrients. 2019 ; 11(5): 1018.

Kahn, H. S. The” lipid accumulation product” performs better than the body mass index for recognizing cardiovascular risk: A population-based comparison. BMC Cardiovascular Disorders,2005; 5(1), 26.

Xiang, S, Hua, F Chen, L Tang, Y Jiang, Liu, Z .Lipid accumulation product is related to metabolic syndrome in women with polycystic ovary syndrome. Experimental and Clinical Endocrinology & Diabetes.2013;121(02), 115–118.

Despre JP, Lemieux I, Bergeron J, Pibarot P, Mathieu P, Larose E et al. Abdominal obesity and the metabolic syndrome: contribution to global cardiometabolic risk. Arterioscler Thromb Vasc Biol 2008; 28: 1039–1049.

Khan HS. The Lipid Accumulation Product Is Better Than BMI for Identifying Diabetes. Diabetes care 2006;29(1).

Adu et al. Lipid accumulation product (LAP) index as a potential risk assessment for cardiovascular risk stratification among type II diabetes mellitus in a Ghanaian population: A cross-sectional study, Cogent Medicine (2019), 6: 1639880.

Cheng Y et al. Fatty Liver Index and Lipid Accumulation Product Can Predict Metabolic Syndrome in Subjects without Fatty Liver Disease. Hindawi Gastroenterology Research and Practice Volume 2017, 9279836, 12 pages.

Chiang and Koo: Lipid accumulation product: a simple and accurate index for predicting metabolic syndrome in Taiwanese people aged 50 and over. BMC Cardiovascular Disorders 2012;12:78 .